Proton magnetic resonance spectroscopy in dementia with Lewy bodies

European Neurology

Volumn 48, Issue 3, 2002, Pages 158-163

  Molina, J A ^a   Garcia Segura J M ^b   Benito Leon J ^c,e   Gomez Escalonilla C ^a   Del Ser, T ^d   Martinez V ^b   Viano J ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL DE MÓSTOLES   (Spain)

^d HOSPITAL SEVERO OCHOA   (Spain)

^e NONE   (Spain)

Author keywords

Dementia; Diffuse Lewy body disease; Lewy bodies; Proton magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATINE PHOSPHATE; CREATININE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; WATER;

AGED; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GRAY MATTER; HUMAN; LEWY BODY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; ONSET AGE; PARIETAL LOBE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE; SYMPTOM; WHITE MATTER;

AGED; BRAIN CHEMISTRY; FEMALE; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS;

EID: 0036427068     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065520     Document Type: Article

References (31)

1. Hansen L, Salmon DF, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M: The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity. Neurology 1990;40:1-8.
2. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK: Senile dementia of Lewy body type. A clinically and neuropathological distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
3. Ala TA, Yang KH, Sung JH, Frey WHI: Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease: A clinicopathological study. J Neurol Neurosurg Psychiatry 1997;62:16-21.
4. Gómez-Isla T, Growdon WB, McNamara M, Newell K, Gomez-Tortosa E, Hedley-Whyte ET, Hyman BT: Clinicopathological correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003-2009.
5. McKeith IG, Ince P, Jaros EB, Fairbairn A, Ballard C, Grace J, Morris CM, Perry RH: What are the relations between Lewy body disease and AD? J Neural Transm Suppl 1998;54:107-116.
6. Hashimoto M, Masliah A: α-Synuclein in Lewy Body Disease and Alzheimer's disease. Brain Pathol 1999;9:707-720.
7. Galvin JE, Uryu K, Lee VM, Trojanowski JQ: Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein. Proc Natl Acad Sci USA 1999;96:13450-13455.
8. Wakabayashi A, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H: Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 1998;96:445-452.
9. Spillantini MG, Schmidt ML, Lee MY, Trojanowski JQ, Jakes R, Goedert M: α-Synuclein in Lewy bodies. Nature 1997;388:839-840.
10. Dickson DW, Davies P, Mayeux R, Crystal H, Horoupian DS, Thompson A, Goldman JE: Diffuse Lewy body disease: Neuropathological and biochemical studies of six patients. Acta Neuropathol (Berl) 1987;75:8-15.
11. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E: Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993;43:1927-1934.
12. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AF, Ince PG, Morris CM, Cheng AV: Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer's disease. Alzheimer Dis Assoc Disord 1993;7:69-79.
13. Shiozaki K, Iseki E, Uchiyama H, Watanabe Y, Haga T, Kameyama K, Ikeda T, Yamamoto T, Kosaka K: Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: Relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999;67:209-213.
14. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411.
15. Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thomas R, Masliah E, Thal LJ: Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Arch Neurol 1999;56:1458-1461.
16. McKeith IG, Perry EK, Perry RH: Report of the second dementia with Lewy bodies international workshop: Diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999;53:902-905.
17. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT: Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999;52:1153-1158.
18. Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT: MRI volumetric study of dementia with Lewy bodies: A comparison with AD and vascular dementia. Neurology 2000;54:1304-1309.
19. Michaelis T, Merboldt KD, Bruhn H, Hänicke W, Frahm J: Absolute concentrations of metabolites in the adult human brain in vivo: Quantification of localized proton MR spectra. Radiology 1993;187:219-227.
20. Danielsen ER, Ross B: Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York, Dekker, 1998.
21. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-198.
22. Fahn S, Elton RL, and members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale; in Fahn S, Marsden CD, Goldstein M, Calne DB (eds): Recent Developments in Parkinson's Disease. New York, McMillan, 1987, pp 153-163.
23. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression, and mortality. Neurology 1967; 17:419-423.
24. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats, RA, Hurd, RE: Automated single-voxel proton MRS: Technical development and multisite verification. Magn Reson Med 1994;31: 365-373.
25. 1H MRS changes in Huntington's disease. Neurology 1999;53:806-812.
26. Henriksen O: In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. NMR Biomed 1995;8:139-148.
27. 1H NMR spectroscopy: N-acetylaspartate, creatine and choline. NMR Biomed 1991;4:47-52.
28. Barker PB, Breiter SN, Soher BJ, Chatham JC, Forder JR, Samphilipo MA, Magee CA, Anderson JH: Quantitative proton spectroscopy of canine brain: In vivo and in vitro correlations. Magn Reson Med 1994;32:157-163.
29. Urenjak J, Williams SR, Gadian DG, Noble M: Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-989.
30. Tedeschi G, Bertolino A, Lundbom N, Bonavita S, Patronas NJ, Duyn JH, Metman LV, Chase TN, Di Chiro G: Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology 1996; 47:696-704.
31. Clarke DD, Sokoloff L: Circulation and energy metabolism of the brain; in Siegel GJ, Agranoff BW, Albers RW, Molinoff PB (eds): Basic Neurochemistry. New York, Raven, 1994, pp 645-680.